Anebulo Pharmaceuticals (ANEB) Operating Expenses (2020 - 2025)
Anebulo Pharmaceuticals (ANEB) posted quarterly Operating Expenses of $2.6 million for Q4 2025, up 1.23% year-over-year from $2.6 million in Q4 2024, and up 15.91% quarter-over-quarter from $2.3 million in Q3 2025.
Anebulo Pharmaceuticals (ANEB) Operating Expenses (2020 - 2025) Analysis & Trends
Anebulo Pharmaceuticals (ANEB) has reported Operating Expenses for 6 consecutive years, with $2.6 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Operating Expenses rose 1.23% year-over-year to $2.6 million; the TTM figure through Dec 2025 stood at $9.1 million (up 13.72% YoY), while the FY2025 annual figure was $9.2 million, up 11.01% from the prior year.
- Operating Expenses climbed to $2.6 million in Q4 2025 per ANEB's latest filing, from $2.3 million in the prior quarter.
- Across five years, Operating Expenses topped out at $3.8 million in Q4 2022 and bottomed at $552131.0 in Q1 2021.
- Historically, Operating Expenses has averaged $2.2 million across 5 years, with a median of $2.4 million in 2024.
- Annual changes were most pronounced in 2021 — Operating Expenses surged 516.19% — and 2024, when it tumbled 46.26%.
- Anebulo Pharmaceuticals' Operating Expenses stood at $1.1 million in 2021, then surged by 255.99% to $3.8 million in 2022, then fell by 27.61% to $2.8 million in 2023, then retreated by 6.24% to $2.6 million in 2024, then advanced by 1.23% to $2.6 million in 2025.
- Business Quant data shows ANEB's Operating Expenses at $2.6 million in Q4 2025, $2.3 million in Q3 2025, and $2.3 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 2.09 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 3.00 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 2.89 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 960.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 1.21 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 1.06 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 427.03 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 541.02 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -784.57 Mn |
| 10 | Anebulo Pharmaceuticals | 16.43 Mn | 16.43 Mn | - | 2.62 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 2.62 Mn |
| Sep 30, 2025 | 2.26 Mn |
| Jun 30, 2025 | 2.33 Mn |
| Mar 31, 2025 | 1.89 Mn |
| Dec 31, 2024 | 2.59 Mn |
| Sep 30, 2024 | 2.41 Mn |
| Jun 30, 2024 | 1.34 Mn |
| Mar 31, 2024 | 1.66 Mn |
| Dec 31, 2023 | 2.76 Mn |
| Sep 30, 2023 | 2.54 Mn |
| Jun 30, 2023 | 2.49 Mn |
| Mar 31, 2023 | 2.86 Mn |
| Dec 31, 2022 | 3.81 Mn |
| Sep 30, 2022 | 2.61 Mn |
| Jun 30, 2022 | 2.33 Mn |
| Mar 31, 2022 | 1.88 Mn |
| Dec 31, 2021 | 1.07 Mn |
| Sep 30, 2021 | 1.55 Mn |
| Jun 30, 2021 | 2.48 Mn |
| Mar 31, 2021 | 552,131.00 |